Suppr超能文献

通过全基因组测序检测到,单个CRISPR-Cas9和TALEN靶向的人类干细胞克隆中脱靶突变的发生率较低。

Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing.

作者信息

Veres Adrian, Gosis Bridget S, Ding Qiurong, Collins Ryan, Ragavendran Ashok, Brand Harrison, Erdin Serkan, Cowan Chad A, Talkowski Michael E, Musunuru Kiran

机构信息

Department of Stem Cell and Regenerative Biology, Harvard University and Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

Department of Stem Cell and Regenerative Biology, Harvard University and Harvard Stem Cell Institute, Cambridge, MA 02138, USA.

出版信息

Cell Stem Cell. 2014 Jul 3;15(1):27-30. doi: 10.1016/j.stem.2014.04.020.

Abstract

Genome editing has attracted wide interest for the generation of cellular models of disease using human pluripotent stem cells and other cell types. CRISPR-Cas systems and TALENs can target desired genomic sites with high efficiency in human cells, but recent publications have led to concern about the extent to which these tools may cause off-target mutagenic effects that could potentially confound disease-modeling studies. Using CRISPR-Cas9 and TALEN targeted human pluripotent stem cell clones, we performed whole-genome sequencing at high coverage in order to assess the degree of mutagenesis across the entire genome. In both types of clones, we found that off-target mutations attributable to the nucleases were very rare. From this analysis, we suggest that, although some cell types may be at risk for off-target mutations, the incidence of such effects in human pluripotent stem cells may be sufficiently low and thus not a significant concern for disease modeling and other applications.

摘要

基因组编辑已引起广泛关注,可用于利用人类多能干细胞和其他细胞类型生成疾病细胞模型。CRISPR-Cas系统和转录激活样效应因子核酸酶(TALENs)可以在人类细胞中高效靶向所需的基因组位点,但最近的出版物引发了人们对这些工具可能在多大程度上导致脱靶诱变效应的担忧,这些效应可能会混淆疾病建模研究。我们使用CRISPR-Cas9和TALEN靶向人类多能干细胞克隆,进行了高覆盖度的全基因组测序,以评估整个基因组的诱变程度。在这两种类型的克隆中,我们发现核酸酶导致的脱靶突变非常罕见。通过这项分析,我们认为,尽管某些细胞类型可能存在脱靶突变的风险,但这种效应在人类多能干细胞中的发生率可能足够低,因此对于疾病建模和其他应用来说并不是一个重大问题。

相似文献

5
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.
Nature. 2016 Jan 28;529(7587):490-5. doi: 10.1038/nature16526. Epub 2016 Jan 6.
6
Concerns regarding 'off-target' activity of genome editing endonucleases.
Plant Physiol Biochem. 2018 Oct;131:22-30. doi: 10.1016/j.plaphy.2018.03.027. Epub 2018 Mar 28.
7
Determining the specificities of TALENs, Cas9, and other genome-editing enzymes.
Methods Enzymol. 2014;546:47-78. doi: 10.1016/B978-0-12-801185-0.00003-9.
8
Efficient Genome Editing in Induced Pluripotent Stem Cells with Engineered Nucleases In Vitro.
Methods Mol Biol. 2017;1521:55-68. doi: 10.1007/978-1-4939-6588-5_4.
10
Discovering the Genome-Wide Activity of CRISPR-Cas Nucleases.
ACS Chem Biol. 2018 Feb 16;13(2):305-308. doi: 10.1021/acschembio.7b00847. Epub 2017 Dec 27.

引用本文的文献

2
Biosafety considerations triggered by genome-editing technologies.
Biosaf Health. 2025 May 13;7(3):141-151. doi: 10.1016/j.bsheal.2025.05.003. eCollection 2025 Jun.
3
Rescue of the disease-associated phenotype in CRISPR-corrected hiPSCs as a therapeutic approach for inherited retinal dystrophies.
Mol Ther Nucleic Acids. 2025 Feb 11;36(1):102482. doi: 10.1016/j.omtn.2025.102482. eCollection 2025 Mar 11.
4
Comprehensive analysis of off-target and on-target effects resulting from liver-directed CRISPR-Cas9-mediated gene targeting with AAV vectors.
Mol Ther Methods Clin Dev. 2024 Nov 4;32(4):101365. doi: 10.1016/j.omtm.2024.101365. eCollection 2024 Dec 12.
5
SeqVerify: An accessible analysis tool for cell line genomic integrity, contamination, and gene editing outcomes.
Stem Cell Reports. 2024 Oct 8;19(10):1505-1515. doi: 10.1016/j.stemcr.2024.08.004. Epub 2024 Sep 12.
6
CRISPR technology in human diseases.
MedComm (2020). 2024 Jul 29;5(8):e672. doi: 10.1002/mco2.672. eCollection 2024 Aug.
7
Beyond the promise: evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics.
Front Bioeng Biotechnol. 2024 Jan 18;11:1339189. doi: 10.3389/fbioe.2023.1339189. eCollection 2023.
8
Novel stem cell technologies are powerful tools to understand the impact of human factors on malaria.
Front Cell Infect Microbiol. 2023 Dec 19;13:1287355. doi: 10.3389/fcimb.2023.1287355. eCollection 2023.
9
Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a "Trojan Horse".
Int J Mol Sci. 2023 Dec 10;24(24):17320. doi: 10.3390/ijms242417320.

本文引用的文献

1
Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases.
Genome Res. 2014 Jan;24(1):132-41. doi: 10.1101/gr.162339.113. Epub 2013 Nov 19.
2
CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity.
Nucleic Acids Res. 2013 Nov;41(20):9584-92. doi: 10.1093/nar/gkt714. Epub 2013 Aug 11.
3
High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity.
Nat Biotechnol. 2013 Sep;31(9):839-43. doi: 10.1038/nbt.2673. Epub 2013 Aug 11.
5
DNA targeting specificity of RNA-guided Cas9 nucleases.
Nat Biotechnol. 2013 Sep;31(9):827-32. doi: 10.1038/nbt.2647. Epub 2013 Jul 21.
6
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells.
Nat Biotechnol. 2013 Sep;31(9):822-6. doi: 10.1038/nbt.2623. Epub 2013 Jun 23.
7
Genome editing of human pluripotent stem cells to generate human cellular disease models.
Dis Model Mech. 2013 Jul;6(4):896-904. doi: 10.1242/dmm.012054. Epub 2013 Jun 10.
8
Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs.
Cell Stem Cell. 2013 Apr 4;12(4):393-4. doi: 10.1016/j.stem.2013.03.006.
9
RNA-programmed genome editing in human cells.
Elife. 2013 Jan 29;2:e00471. doi: 10.7554/eLife.00471.
10
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease.
Nat Biotechnol. 2013 Mar;31(3):230-2. doi: 10.1038/nbt.2507. Epub 2013 Jan 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验